Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-09-11

AUTHORS

Hirohisa Nakamae, Masahide Yamamoto, Emiko Sakaida, Yoshinobu Kanda, Ken Ohmine, Takaaki Ono, Itaru Matsumura, Maho Ishikawa, Makoto Aoki, Akio Maki, Hirohiko Shibayama

ABSTRACT

In the 10-year analysis of Japanese patients with newly diagnosed CML-CP in the ENESTnd trial, nilotinib yielded higher cumulative response rates. There were no new occurrences of disease progression or deaths since the 5-year analysis. Cumulative 10-year rates of MMR and MR4.5 were higher in the nilotinib arms [300 mg twice daily (BID), 86.2% and 69.0%, respectively; 400 mg BID, 78.3% and 69.6%, respectively] than the imatinib arm (400 mg once daily, 60.0% and 48.0%, respectively). Nasopharyngitis (85.7%, 77.3%, 79.2%), rash (50.0%, 68.2%, 37.5%), headache (39.3%, 45.5%, 25.0%), and back pain (39.3%, 50.0%, 29.2%) were the most frequently reported all-grade adverse events (AEs) for nilotinib 300 and 400 mg BID and imatinib, respectively. Cardiovascular AEs were more common with nilotinib than with imatinib. More patients on nilotinib had pre-diabetic and diabetic levels of HbA1c (300 mg BID, 17.9% and 10.7%, respectively; 400 mg BID, 22.7% and 18.2%, respectively) compared with imatinib (4.2% each). Overall, 10-year results from the Japanese cohort are consistent with prior results from the full ENESTnd cohort and the Japanese subgroup, and continue to support the long-term use of nilotinib in Japanese patients with newly diagnosed CML-CP, but with proper monitoring and management of comorbidities. More... »

PAGES

33-42

References to SciGraph publications

  • 2017-10-26. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2016-02-03. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial in LEUKEMIA
  • 2011-04-27. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2021-01-07. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis in LEUKEMIA
  • 2019-04-23. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2017-03-24. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2020-03-03. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia in LEUKEMIA
  • 2009-01. Targeting cancer with small molecule kinase inhibitors in NATURE REVIEWS CANCER
  • 2020-04-11. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 1996-05. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12185-021-03216-5

    DOI

    http://dx.doi.org/10.1007/s12185-021-03216-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141037263

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34508295


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Asians", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blast Crisis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Progression", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Follow-Up Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Imatinib Mesylate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein-Tyrosine Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrimidines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Hematology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.261445.0", 
              "name": [
                "Hematology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakamae", 
            "givenName": "Hirohisa", 
            "id": "sg:person.01014223462.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.265073.5", 
              "name": [
                "Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yamamoto", 
            "givenName": "Masahide", 
            "id": "sg:person.0605437164.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605437164.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Chiba University Hospital, Chiba, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411321.4", 
              "name": [
                "Department of Hematology, Chiba University Hospital, Chiba, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakaida", 
            "givenName": "Emiko", 
            "id": "sg:person.0775302360.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775302360.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.415020.2", 
              "name": [
                "Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kanda", 
            "givenName": "Yoshinobu", 
            "id": "sg:person.0617055140.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617055140.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan", 
              "id": "http://www.grid.ac/institutes/grid.415016.7", 
              "name": [
                "Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ohmine", 
            "givenName": "Ken", 
            "id": "sg:person.01144457051.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144457051.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.505613.4", 
              "name": [
                "Division of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ono", 
            "givenName": "Takaaki", 
            "id": "sg:person.0754570043.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754570043.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Kindai University Hospital, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.413111.7", 
              "name": [
                "Department of Hematology, Kindai University Hospital, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matsumura", 
            "givenName": "Itaru", 
            "id": "sg:person.0760470165.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.412377.4", 
              "name": [
                "Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ishikawa", 
            "givenName": "Maho", 
            "id": "sg:person.01317542701.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317542701.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novartis Pharma KK, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418599.8", 
              "name": [
                "Novartis Pharma KK, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Aoki", 
            "givenName": "Makoto", 
            "id": "sg:person.010025131125.50", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025131125.50"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Novartis Pharma KK, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418599.8", 
              "name": [
                "Novartis Pharma KK, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Maki", 
            "givenName": "Akio", 
            "id": "sg:person.014420647445.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014420647445.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan", 
              "id": "http://www.grid.ac/institutes/grid.136593.b", 
              "name": [
                "Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shibayama", 
            "givenName": "Hirohiko", 
            "id": "sg:person.01273323113.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s41375-020-01111-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1134383975", 
              "https://doi.org/10.1038/s41375-020-01111-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0596-561", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051513257", 
              "https://doi.org/10.1038/nm0596-561"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-020-02878-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1126624340", 
              "https://doi.org/10.1007/s12185-020-02878-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2559", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001079875", 
              "https://doi.org/10.1038/nrc2559"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-017-2353-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092351625", 
              "https://doi.org/10.1007/s12185-017-2353-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-019-0729-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113639064", 
              "https://doi.org/10.1186/s13045-019-0729-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-011-0841-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035334251", 
              "https://doi.org/10.1007/s12185-011-0841-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2016.5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041273297", 
              "https://doi.org/10.1038/leu.2016.5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-017-2208-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084034348", 
              "https://doi.org/10.1007/s12185-017-2208-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-020-0776-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1125320161", 
              "https://doi.org/10.1038/s41375-020-0776-2"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-09-11", 
        "datePublishedReg": "2021-09-11", 
        "description": "In the 10-year analysis of Japanese patients with newly diagnosed CML-CP in the ENESTnd trial, nilotinib yielded higher cumulative response rates. There were no new occurrences of disease progression or deaths since the 5-year analysis. Cumulative 10-year rates of MMR and MR4.5 were higher in the nilotinib arms [300\u00a0mg twice daily (BID), 86.2% and 69.0%, respectively; 400\u00a0mg BID, 78.3% and 69.6%, respectively] than the imatinib arm (400\u00a0mg once daily, 60.0% and 48.0%, respectively). Nasopharyngitis (85.7%, 77.3%, 79.2%), rash (50.0%, 68.2%, 37.5%), headache (39.3%, 45.5%, 25.0%), and back pain (39.3%, 50.0%, 29.2%) were the most frequently reported all-grade adverse events (AEs) for nilotinib 300 and 400\u00a0mg BID and imatinib, respectively. Cardiovascular AEs were more common with nilotinib than with imatinib. More patients on nilotinib had pre-diabetic and diabetic levels of HbA1c (300\u00a0mg BID, 17.9% and 10.7%, respectively; 400\u00a0mg BID, 22.7% and 18.2%, respectively) compared with imatinib (4.2% each). Overall, 10-year results from the Japanese cohort are consistent with prior results from the full ENESTnd cohort and the Japanese subgroup, and continue to support the long-term use of nilotinib in Japanese patients with newly diagnosed CML-CP, but with proper monitoring and management of comorbidities.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12185-021-03216-5", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1076985", 
            "issn": [
              "0925-5710", 
              "1865-3774"
            ], 
            "name": "International Journal of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "115"
          }
        ], 
        "keywords": [
          "adverse events", 
          "Japanese patients", 
          "ENESTnd trial", 
          "CML-CP", 
          "Japanese subgroup", 
          "grade adverse events", 
          "cardiovascular adverse events", 
          "management of comorbidities", 
          "cumulative response rate", 
          "chronic myeloid leukemia", 
          "long-term use", 
          "nilotinib arm", 
          "imatinib arm", 
          "nilotinib 300", 
          "more patients", 
          "back pain", 
          "chronic phase", 
          "disease progression", 
          "myeloid leukemia", 
          "Japanese cohort", 
          "diabetic levels", 
          "response rate", 
          "patients", 
          "nilotinib", 
          "imatinib", 
          "cohort", 
          "trials", 
          "subgroups", 
          "nasopharyngitis", 
          "proper monitoring", 
          "MR4.5", 
          "comorbidities", 
          "pain", 
          "headache", 
          "arm", 
          "leukemia", 
          "progression", 
          "death", 
          "MMR", 
          "rate", 
          "management", 
          "levels", 
          "occurrence", 
          "events", 
          "analysis", 
          "results", 
          "monitoring", 
          "use", 
          "new occurrence", 
          "prior results", 
          "bid", 
          "phase"
        ], 
        "name": "Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow\u2011up of the Japanese subgroup of the randomized ENESTnd trial", 
        "pagination": "33-42", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141037263"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12185-021-03216-5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34508295"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12185-021-03216-5", 
          "https://app.dimensions.ai/details/publication/pub.1141037263"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:42", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_884.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12185-021-03216-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03216-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03216-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03216-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03216-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    326 TRIPLES      21 PREDICATES      106 URIs      88 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12185-021-03216-5 schema:about N1469add6eaa94fd1b196f55074b1a7f0
    2 N3010776f580f43528e0519d1e4af0446
    3 N40ffcea7c31f409296e1464b423848b9
    4 N58e8a4c7723341f7a3c6199c0a0f692c
    5 N5d601a8be5ae4161a5a0058c75a53295
    6 N7281096bde9241dba417337ada03da8c
    7 N78082b9b774e41a09e1882c254a97617
    8 N7ac2fd930dd94fd2a2f957a988d13e19
    9 N92e8f77da4a2496a90d158baa867ccc6
    10 N9421547a0f3247808e2ad800edf5f2c4
    11 N9c9788baac124e3681f5b1ea0b42d0cd
    12 Nad525ee767294647ba04592f992bbc12
    13 Nb30e19b3ccbf495190fc1bd8c91311c7
    14 Nd2c3907df72946b7897eb17d7e678754
    15 Nda7be8ddd69d4989b7d8a9b298c412d4
    16 Ndd97989da5f243a08d4e839f4b55e148
    17 Ne89c0ea24a78409ba0c83e52583c2d3d
    18 Nf44a0ab14b00444eaa09d073988dc845
    19 Nf9e5aea8f3b345cdb1ab58664dc2220a
    20 anzsrc-for:11
    21 anzsrc-for:1102
    22 schema:author N0f12a39575d846d2b5de7f6490cefaf4
    23 schema:citation sg:pub.10.1007/s12185-011-0841-8
    24 sg:pub.10.1007/s12185-017-2208-2
    25 sg:pub.10.1007/s12185-017-2353-7
    26 sg:pub.10.1007/s12185-020-02878-x
    27 sg:pub.10.1038/leu.2016.5
    28 sg:pub.10.1038/nm0596-561
    29 sg:pub.10.1038/nrc2559
    30 sg:pub.10.1038/s41375-020-01111-2
    31 sg:pub.10.1038/s41375-020-0776-2
    32 sg:pub.10.1186/s13045-019-0729-2
    33 schema:datePublished 2021-09-11
    34 schema:datePublishedReg 2021-09-11
    35 schema:description In the 10-year analysis of Japanese patients with newly diagnosed CML-CP in the ENESTnd trial, nilotinib yielded higher cumulative response rates. There were no new occurrences of disease progression or deaths since the 5-year analysis. Cumulative 10-year rates of MMR and MR4.5 were higher in the nilotinib arms [300 mg twice daily (BID), 86.2% and 69.0%, respectively; 400 mg BID, 78.3% and 69.6%, respectively] than the imatinib arm (400 mg once daily, 60.0% and 48.0%, respectively). Nasopharyngitis (85.7%, 77.3%, 79.2%), rash (50.0%, 68.2%, 37.5%), headache (39.3%, 45.5%, 25.0%), and back pain (39.3%, 50.0%, 29.2%) were the most frequently reported all-grade adverse events (AEs) for nilotinib 300 and 400 mg BID and imatinib, respectively. Cardiovascular AEs were more common with nilotinib than with imatinib. More patients on nilotinib had pre-diabetic and diabetic levels of HbA1c (300 mg BID, 17.9% and 10.7%, respectively; 400 mg BID, 22.7% and 18.2%, respectively) compared with imatinib (4.2% each). Overall, 10-year results from the Japanese cohort are consistent with prior results from the full ENESTnd cohort and the Japanese subgroup, and continue to support the long-term use of nilotinib in Japanese patients with newly diagnosed CML-CP, but with proper monitoring and management of comorbidities.
    36 schema:genre article
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N193eb014046d4b4a8bf6c0228fea50c3
    39 Nb99985e27ad046f7a396edbb53e28fb0
    40 sg:journal.1076985
    41 schema:keywords CML-CP
    42 ENESTnd trial
    43 Japanese cohort
    44 Japanese patients
    45 Japanese subgroup
    46 MMR
    47 MR4.5
    48 adverse events
    49 analysis
    50 arm
    51 back pain
    52 bid
    53 cardiovascular adverse events
    54 chronic myeloid leukemia
    55 chronic phase
    56 cohort
    57 comorbidities
    58 cumulative response rate
    59 death
    60 diabetic levels
    61 disease progression
    62 events
    63 grade adverse events
    64 headache
    65 imatinib
    66 imatinib arm
    67 leukemia
    68 levels
    69 long-term use
    70 management
    71 management of comorbidities
    72 monitoring
    73 more patients
    74 myeloid leukemia
    75 nasopharyngitis
    76 new occurrence
    77 nilotinib
    78 nilotinib 300
    79 nilotinib arm
    80 occurrence
    81 pain
    82 patients
    83 phase
    84 prior results
    85 progression
    86 proper monitoring
    87 rate
    88 response rate
    89 results
    90 subgroups
    91 trials
    92 use
    93 schema:name Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial
    94 schema:pagination 33-42
    95 schema:productId N377a3019418f41a8a7a96be59b1eef8c
    96 Nbedac1656b4c462f9f1ec75fb01179ad
    97 Ne25b1c36137a43c79773fc49a325a026
    98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141037263
    99 https://doi.org/10.1007/s12185-021-03216-5
    100 schema:sdDatePublished 2022-12-01T06:42
    101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    102 schema:sdPublisher N395d3a59667849deb4b8045ae53567d9
    103 schema:url https://doi.org/10.1007/s12185-021-03216-5
    104 sgo:license sg:explorer/license/
    105 sgo:sdDataset articles
    106 rdf:type schema:ScholarlyArticle
    107 N04a0d3b385f14c26a6d81d87785552a6 rdf:first sg:person.0617055140.49
    108 rdf:rest Na1b36e04bb9d494db2413a5eaaac6d13
    109 N0f12a39575d846d2b5de7f6490cefaf4 rdf:first sg:person.01014223462.98
    110 rdf:rest N68eea5bc584d4c88a6cbd3030b53aa72
    111 N1469add6eaa94fd1b196f55074b1a7f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Follow-Up Studies
    113 rdf:type schema:DefinedTerm
    114 N193eb014046d4b4a8bf6c0228fea50c3 schema:volumeNumber 115
    115 rdf:type schema:PublicationVolume
    116 N2094dfae65b44777ba2530a9cd30e3b6 rdf:first sg:person.01273323113.98
    117 rdf:rest rdf:nil
    118 N279c99c4d1c94a5bae5d59d817e947df rdf:first sg:person.01317542701.38
    119 rdf:rest N4a0a6d37b6df4015848f121c5e3c1eab
    120 N3010776f580f43528e0519d1e4af0446 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Middle Aged
    122 rdf:type schema:DefinedTerm
    123 N377a3019418f41a8a7a96be59b1eef8c schema:name doi
    124 schema:value 10.1007/s12185-021-03216-5
    125 rdf:type schema:PropertyValue
    126 N395d3a59667849deb4b8045ae53567d9 schema:name Springer Nature - SN SciGraph project
    127 rdf:type schema:Organization
    128 N40ffcea7c31f409296e1464b423848b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Imatinib Mesylate
    130 rdf:type schema:DefinedTerm
    131 N4a0a6d37b6df4015848f121c5e3c1eab rdf:first sg:person.010025131125.50
    132 rdf:rest N77703302aa26484484996822895ef127
    133 N58e8a4c7723341f7a3c6199c0a0f692c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Young Adult
    135 rdf:type schema:DefinedTerm
    136 N5d601a8be5ae4161a5a0058c75a53295 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Asians
    138 rdf:type schema:DefinedTerm
    139 N68eea5bc584d4c88a6cbd3030b53aa72 rdf:first sg:person.0605437164.86
    140 rdf:rest Nd1241fb67d3241359770051bb269fedf
    141 N7281096bde9241dba417337ada03da8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Female
    143 rdf:type schema:DefinedTerm
    144 N77703302aa26484484996822895ef127 rdf:first sg:person.014420647445.00
    145 rdf:rest N2094dfae65b44777ba2530a9cd30e3b6
    146 N78082b9b774e41a09e1882c254a97617 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Blast Crisis
    148 rdf:type schema:DefinedTerm
    149 N7ac2fd930dd94fd2a2f957a988d13e19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Protein Kinase Inhibitors
    151 rdf:type schema:DefinedTerm
    152 N92e8f77da4a2496a90d158baa867ccc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Protein-Tyrosine Kinases
    154 rdf:type schema:DefinedTerm
    155 N9421547a0f3247808e2ad800edf5f2c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Adult
    157 rdf:type schema:DefinedTerm
    158 N9c9788baac124e3681f5b1ea0b42d0cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Aged
    160 rdf:type schema:DefinedTerm
    161 Na1b36e04bb9d494db2413a5eaaac6d13 rdf:first sg:person.01144457051.28
    162 rdf:rest Nc71dbecc50c649cd87d29dbd14bff5d7
    163 Nad525ee767294647ba04592f992bbc12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Aged, 80 and over
    165 rdf:type schema:DefinedTerm
    166 Nb30e19b3ccbf495190fc1bd8c91311c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Male
    168 rdf:type schema:DefinedTerm
    169 Nb99985e27ad046f7a396edbb53e28fb0 schema:issueNumber 1
    170 rdf:type schema:PublicationIssue
    171 Nbedac1656b4c462f9f1ec75fb01179ad schema:name pubmed_id
    172 schema:value 34508295
    173 rdf:type schema:PropertyValue
    174 Nc71dbecc50c649cd87d29dbd14bff5d7 rdf:first sg:person.0754570043.19
    175 rdf:rest Nfe4c719457e945b295404af5340cdbd4
    176 Nd1241fb67d3241359770051bb269fedf rdf:first sg:person.0775302360.96
    177 rdf:rest N04a0d3b385f14c26a6d81d87785552a6
    178 Nd2c3907df72946b7897eb17d7e678754 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Humans
    180 rdf:type schema:DefinedTerm
    181 Nda7be8ddd69d4989b7d8a9b298c412d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Disease Progression
    183 rdf:type schema:DefinedTerm
    184 Ndd97989da5f243a08d4e839f4b55e148 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Pyrimidines
    186 rdf:type schema:DefinedTerm
    187 Ne25b1c36137a43c79773fc49a325a026 schema:name dimensions_id
    188 schema:value pub.1141037263
    189 rdf:type schema:PropertyValue
    190 Ne89c0ea24a78409ba0c83e52583c2d3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Treatment Outcome
    192 rdf:type schema:DefinedTerm
    193 Nf44a0ab14b00444eaa09d073988dc845 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    195 rdf:type schema:DefinedTerm
    196 Nf9e5aea8f3b345cdb1ab58664dc2220a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Time Factors
    198 rdf:type schema:DefinedTerm
    199 Nfe4c719457e945b295404af5340cdbd4 rdf:first sg:person.0760470165.13
    200 rdf:rest N279c99c4d1c94a5bae5d59d817e947df
    201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Medical and Health Sciences
    203 rdf:type schema:DefinedTerm
    204 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    205 schema:name Cardiorespiratory Medicine and Haematology
    206 rdf:type schema:DefinedTerm
    207 sg:journal.1076985 schema:issn 0925-5710
    208 1865-3774
    209 schema:name International Journal of Hematology
    210 schema:publisher Springer Nature
    211 rdf:type schema:Periodical
    212 sg:person.010025131125.50 schema:affiliation grid-institutes:grid.418599.8
    213 schema:familyName Aoki
    214 schema:givenName Makoto
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025131125.50
    216 rdf:type schema:Person
    217 sg:person.01014223462.98 schema:affiliation grid-institutes:grid.261445.0
    218 schema:familyName Nakamae
    219 schema:givenName Hirohisa
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98
    221 rdf:type schema:Person
    222 sg:person.01144457051.28 schema:affiliation grid-institutes:grid.415016.7
    223 schema:familyName Ohmine
    224 schema:givenName Ken
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144457051.28
    226 rdf:type schema:Person
    227 sg:person.01273323113.98 schema:affiliation grid-institutes:grid.136593.b
    228 schema:familyName Shibayama
    229 schema:givenName Hirohiko
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98
    231 rdf:type schema:Person
    232 sg:person.01317542701.38 schema:affiliation grid-institutes:grid.412377.4
    233 schema:familyName Ishikawa
    234 schema:givenName Maho
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317542701.38
    236 rdf:type schema:Person
    237 sg:person.014420647445.00 schema:affiliation grid-institutes:grid.418599.8
    238 schema:familyName Maki
    239 schema:givenName Akio
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014420647445.00
    241 rdf:type schema:Person
    242 sg:person.0605437164.86 schema:affiliation grid-institutes:grid.265073.5
    243 schema:familyName Yamamoto
    244 schema:givenName Masahide
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605437164.86
    246 rdf:type schema:Person
    247 sg:person.0617055140.49 schema:affiliation grid-institutes:grid.415020.2
    248 schema:familyName Kanda
    249 schema:givenName Yoshinobu
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617055140.49
    251 rdf:type schema:Person
    252 sg:person.0754570043.19 schema:affiliation grid-institutes:grid.505613.4
    253 schema:familyName Ono
    254 schema:givenName Takaaki
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754570043.19
    256 rdf:type schema:Person
    257 sg:person.0760470165.13 schema:affiliation grid-institutes:grid.413111.7
    258 schema:familyName Matsumura
    259 schema:givenName Itaru
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13
    261 rdf:type schema:Person
    262 sg:person.0775302360.96 schema:affiliation grid-institutes:grid.411321.4
    263 schema:familyName Sakaida
    264 schema:givenName Emiko
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775302360.96
    266 rdf:type schema:Person
    267 sg:pub.10.1007/s12185-011-0841-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035334251
    268 https://doi.org/10.1007/s12185-011-0841-8
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1007/s12185-017-2208-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084034348
    271 https://doi.org/10.1007/s12185-017-2208-2
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1007/s12185-017-2353-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092351625
    274 https://doi.org/10.1007/s12185-017-2353-7
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1007/s12185-020-02878-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1126624340
    277 https://doi.org/10.1007/s12185-020-02878-x
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/leu.2016.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041273297
    280 https://doi.org/10.1038/leu.2016.5
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/nm0596-561 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051513257
    283 https://doi.org/10.1038/nm0596-561
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/nrc2559 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001079875
    286 https://doi.org/10.1038/nrc2559
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1038/s41375-020-01111-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134383975
    289 https://doi.org/10.1038/s41375-020-01111-2
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1038/s41375-020-0776-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125320161
    292 https://doi.org/10.1038/s41375-020-0776-2
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1186/s13045-019-0729-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113639064
    295 https://doi.org/10.1186/s13045-019-0729-2
    296 rdf:type schema:CreativeWork
    297 grid-institutes:grid.136593.b schema:alternateName Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
    298 schema:name Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
    299 rdf:type schema:Organization
    300 grid-institutes:grid.261445.0 schema:alternateName Hematology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan
    301 schema:name Hematology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, 545-8585, Osaka, Japan
    302 rdf:type schema:Organization
    303 grid-institutes:grid.265073.5 schema:alternateName Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan
    304 schema:name Department of Hematology, Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan
    305 rdf:type schema:Organization
    306 grid-institutes:grid.411321.4 schema:alternateName Department of Hematology, Chiba University Hospital, Chiba, Japan
    307 schema:name Department of Hematology, Chiba University Hospital, Chiba, Japan
    308 rdf:type schema:Organization
    309 grid-institutes:grid.412377.4 schema:alternateName Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
    310 schema:name Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
    311 rdf:type schema:Organization
    312 grid-institutes:grid.413111.7 schema:alternateName Department of Hematology, Kindai University Hospital, Osaka, Japan
    313 schema:name Department of Hematology, Kindai University Hospital, Osaka, Japan
    314 rdf:type schema:Organization
    315 grid-institutes:grid.415016.7 schema:alternateName Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan
    316 schema:name Division of Hematology, Jichi Medical University Hospital, Tochigi, Japan
    317 rdf:type schema:Organization
    318 grid-institutes:grid.415020.2 schema:alternateName Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan
    319 schema:name Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan
    320 rdf:type schema:Organization
    321 grid-institutes:grid.418599.8 schema:alternateName Novartis Pharma KK, Tokyo, Japan
    322 schema:name Novartis Pharma KK, Tokyo, Japan
    323 rdf:type schema:Organization
    324 grid-institutes:grid.505613.4 schema:alternateName Division of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan
    325 schema:name Division of Hematology, Hamamatsu University School of Medicine, Shizuoka, Japan
    326 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...